相似文献
1
The mTOR signaling pathway as a treatment target for intracranial neoplasms.
Neuro Oncol. 2015 Feb;17(2):189-99. doi: 10.1093/neuonc/nou164. Epub 2014 Aug 27.
2
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma.
Oncotarget. 2016 May 31;7(22):33440-50. doi: 10.18632/oncotarget.7961.
3
Role of mTOR in glioblastoma.
Gene. 2016 Jan 10;575(2 Pt 1):187-90. doi: 10.1016/j.gene.2015.08.060. Epub 2015 Sep 1.
4
The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.
Clin Cancer Res. 2013 Oct 15;19(20):5722-32. doi: 10.1158/1078-0432.CCR-13-0527. Epub 2013 Sep 12.
5
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.
PLoS Med. 2008 Jan 22;5(1):e8. doi: 10.1371/journal.pmed.0050008.
6
A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma.
Cancer Cell. 2017 Mar 13;31(3):424-435. doi: 10.1016/j.ccell.2017.01.014.
7
RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
Anticancer Drugs. 2016 Jul;27(6):475-87. doi: 10.1097/CAD.0000000000000354.
8
Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
Oncol Rep. 2013 Oct;30(4):1645-50. doi: 10.3892/or.2013.2625. Epub 2013 Jul 18.
9
Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Clin Cancer Res. 2014 Nov 15;20(22):5756-67. doi: 10.1158/1078-0432.CCR-13-3389. Epub 2014 Oct 14.
10
Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Adv Biol Regul. 2015 Jan;57:64-74. doi: 10.1016/j.jbior.2014.09.004. Epub 2014 Sep 18.
引用本文的文献
1
Pediatric low-grade brainstem glioma: a review of current diagnosis and treatment paradigms in the molecular era.
Childs Nerv Syst. 2025 Aug 18;41(1):261. doi: 10.1007/s00381-025-06924-z.
2
Meningioma: Novel Diagnostic and Therapeutic Approaches.
Biomedicines. 2025 Mar 7;13(3):659. doi: 10.3390/biomedicines13030659.
3
European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selection.
Neuro Oncol. 2025 May 15;27(4):869-883. doi: 10.1093/neuonc/noae253.
4
Extra-temporal pediatric low-grade gliomas and epilepsy.
Childs Nerv Syst. 2024 Oct;40(10):3309-3327. doi: 10.1007/s00381-024-06573-8. Epub 2024 Aug 27.
5
Intramedullary pediatric low-grade glioma of the spine.
Childs Nerv Syst. 2024 Oct;40(10):3107-3117. doi: 10.1007/s00381-024-06499-1. Epub 2024 Jun 21.
6
Novel Advances in Treatment of Meningiomas: Prognostic and Therapeutic Implications.
Cancers (Basel). 2023 Sep 12;15(18):4521. doi: 10.3390/cancers15184521.
7
Unlocking the power of precision medicine for pediatric low-grade gliomas: molecular characterization for targeted therapies with enhanced safety and efficacy.
Front Oncol. 2023 Jun 15;13:1204829. doi: 10.3389/fonc.2023.1204829. eCollection 2023.
8
Significance of molecular diagnostics for therapeutic decision-making in recurrent glioma.
Neurooncol Adv. 2023 May 12;5(1):vdad060. doi: 10.1093/noajnl/vdad060. eCollection 2023 Jan-Dec.
9
Medical Treatment of Pediatric Low-Grade Glioma.
Brain Tumor Res Treat. 2022 Oct;10(4):221-225. doi: 10.14791/btrt.2022.0039.
10
Co-Targeting MAP Kinase and Pi3K-Akt-mTOR Pathways in Meningioma: Preclinical Study of Alpelisib and Trametinib.
Cancers (Basel). 2022 Sep 13;14(18):4448. doi: 10.3390/cancers14184448.
本文引用的文献
1
Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
Biochem Pharmacol. 2014 Aug 1;90(3):197-207. doi: 10.1016/j.bcp.2014.05.011. Epub 2014 May 24.
2
In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways.
Int J Mol Sci. 2014 May 16;15(5):8773-94. doi: 10.3390/ijms15058773.
3
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
Neuro Oncol. 2014 Apr;16(4):567-78. doi: 10.1093/neuonc/not247. Epub 2014 Jan 26.
4
mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.
Neuro Oncol. 2014 Apr;16(4):493-504. doi: 10.1093/neuonc/not242. Epub 2014 Jan 10.
5
mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.
Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):409-14. doi: 10.1073/pnas.1314469111. Epub 2013 Dec 23.
6
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Science. 2014 Jan 10;343(6167):189-193. doi: 10.1126/science.1239947. Epub 2013 Dec 12.
7
Significance of Akt activation and AKT gene increases in soft tissue tumors.
Hum Pathol. 2014 Jan;45(1):127-36. doi: 10.1016/j.humpath.2013.06.024.
8
Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.
Neuro Oncol. 2014 Jan;16(2):292-7. doi: 10.1093/neuonc/not150. Epub 2013 Dec 4.
9
Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target.
Neuro Oncol. 2013 Dec;15(12):1604-14. doi: 10.1093/neuonc/not132. Epub 2013 Nov 6.
10
CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010.
Neuro Oncol. 2013 Nov;15 Suppl 2(Suppl 2):ii1-56. doi: 10.1093/neuonc/not151.
Zotero 插件